Sp1076
ADVANCES IN ENDOSCOPIC ERADICATION THERAPY - PUSHING THE BOUNDARIES
Date
May 21, 2024
Presenter
Amsterdam UMC
Tracks
Related Products
STATE OF THE ART IN ENDOSCOIC ERADICATION THERAPY FOR BARRETT'S RELATED NEOPLASIA
Barrett's esophagus is the only precancerous condition for esophageal adenocarcinoma; a cancer that is associated with rising incidence and high morbidity and mortality rates…
BARRETT'S SURVEILLANCE: IS THERE ANYTHING REALLY BETER THAN THE SEATTLE PROTOCAL?
A variety of new developments in the realms of screening and surveillance of Barrett's esophagus have occurred in recent years. This session will focus on the current evidence base for risk assessment algorithms to enhance screening uptake, new screening tools and obstacles to implementation…
LOW RECURRENCE RATES AFTER ENDOSCOPIC RESECTION (R0) OF HIGH-RISK T1 ADENOCARCINOMA IN BARRETT’S ESOPHAGUS SUPPORT A STRICT ENDOSCOPIC SURVEILLANCE STRATEGY: PRELIMINARY RESULTS OF A PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT STUDY (PREFER)
Optimal management following radical endoscopic resection (R0 ER) of T1 esophageal adenocarcinoma (EAC) is still a matter of debate due to conflicting reports on the risk for lymph node metastases (LNM). In case of histological risk factors for LNM, i.e…
ADDITIONAL VALUE OF EXPERT CARE FOR PATIENTS WITH ULTRA-LONG BARRETT'S ESOPHAGUS IN THE NETHERLANDS: RESULTS OF THE NATIONWIDE BARRETT EXPERT CENTER REGISTRY.
The neoplastic progression risk in Barrett’s Esophagus (BE) increases with increasing BE length. Therefore, some guidelines recommend that patients with ultra long-segment BE ≥10cm (ULS-BE) are referred to an expert center, however, recommendations on further management are lacking…
